Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) versus Cidara Therapeutics (NASDAQ:CDTX) Head-To-Head Survey

Cidara Therapeutics (NASDAQ:CDTX) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Volatility & Risk

Cidara Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Quantum Genomics Société Anonyme has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Profitability

This table compares Cidara Therapeutics and Quantum Genomics Société Anonyme’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cidara Therapeutics	-289.05%	-109.89%	-34.82%
Quantum Genomics Société Anonyme	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and price targets for Cidara Therapeutics and Quantum Genomics Société Anonyme, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cidara Therapeutics	0	0	3	1	3.25
Quantum Genomics Société Anonyme	0	0	0	0	N/A

Cidara Therapeutics currently has a consensus target price of $29.67, suggesting a potential upside of 131.23%. Given Cidara Therapeutics’ higher possible upside, equities research analysts plainly believe Cidara Therapeutics is more favorable than Quantum Genomics Société Anonyme.

Insider & Institutional Ownership

35.8% of Cidara Therapeutics shares are owned by institutional investors. 7.6% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Cidara Therapeutics and Quantum Genomics Société Anonyme”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cidara Therapeutics	$53.87 million	1.09	-$22.93 million	($7.68)	-1.67
Quantum Genomics Société Anonyme	N/A	N/A	N/A	N/A	N/A

Quantum Genomics Société Anonyme has lower revenue, but higher earnings than Cidara Therapeutics.

Summary

Cidara Therapeutics beats Quantum Genomics Société Anonyme on 7 of the 10 factors compared between the two stocks.

About Cidara Therapeutics

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

About Quantum Genomics Société Anonyme

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.